ASCO 2024 | INTerpath-001: V940, a neoantigen therapy, with pembrolizumab in melanoma
Jeffrey Weber, MD, PhD, NYU Langone Health, New York, NY, provides an overview of the Phase III INTerpath-001 trial (NCT05933577), which assesses the efficacy and safety of combining adjuvant pembrolizumab with the individualized neoantigen therapy V940 in patients with resected high-risk stage II-IV melanoma. Eligible patients are stratified by risk and age and will receive pembrolizumab every 6 weeks plus either V940 or placebo every 3 weeks. Primary endpoint is recurrence-free survival, and secondary endpoints including distant metastasis-free survival, overall survival, safety, and quality of life. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Biond; Evaxion Biotech; OncoC4; Turnstone Bio
Honoraria – Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Turnstone Bio; Ultimovacs; WindMIL
Consulting or Advisory Role – Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Roche; Sellas Life Sciences; Turnstone Bio; Turnstone Bio; Ultimovacs; WindMIL
Research Funding – Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property – named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses – Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Moderna Therapeutics; Novartis; Roche
